Baidu
map

NEJM:糖尿病相关并发症的发病趋势仍不乐观

2014-04-22 佚名 dxy

近年来,随着新型有效的药物治疗和医疗手段的推广,糖尿病治疗、自我管理行为和危险因素控制的持续改进,成人糖尿病患者的预防保健有大幅改善。 为了调查1990年至2010年期间,美国糖尿病相关并发症的发病趋势,来自美国埃默里大学的Gregg教授及其团队进行了一项研究,研究结果发表在2014年04月17日的The New England journal of medicine杂志上。 该研究的研究数据来源

近年来,随着新型有效的药物治疗和医疗手段的推广,糖尿病治疗、自我管理行为和危险因素控制的持续改进,成人糖尿病患者的预防保健有大幅改善。

为了调查1990年至2010年期间,美国糖尿病相关并发症的发病趋势,来自美国埃默里大学的Gregg教授及其团队进行了一项研究,研究结果发表在2014年04月17日的The New England journal of medicine杂志上。

该研究的研究数据来源于国民健康访问调查、国立医院出院调查、美国肾脏病数据系统、以及美国国家生命统计系统,比较1990年至2010年期间下肢截肢、终末期肾脏疾病、急性心肌梗塞、卒中和高血糖危险导致死亡的发生率,并用2000年美国人口数据对发病率进行年龄标准化处理。

该研究发现,1990年至2010年期间,所有5种糖尿病相关并发症的发病率都在下降,其中相对降幅最大的是急性心肌梗塞和高血糖危象导致死亡,分别下降了67.8%和64.4%;其次是卒中和下肢截肢,分别下了52.7%和51.4%;降幅最小的是终末期肾脏疾病,仅下降28.3%。急性心肌梗塞病例数绝对降幅最大,每10000人减少95.6例,而高血糖危象导致死亡数绝对降幅最小,每10000人减少2.7例。

成年糖尿病患者中并发症发病率降幅大于成年非糖尿病患者,导致糖尿病相关并发症相对风险下降。将总人口以率来表示时,糖尿病患病率变化也可影响并发症发生率,急性心肌梗塞和高血糖危象导致死亡发生率下降,但截肢、卒中和终末期肾脏病发生率没有变化。

该研究提示,过去20年期间,糖尿病相关并发症发生率有大幅下降,但是,由于糖尿病患病率的持续增加,糖尿病相关并发症仍然是一个巨大的疾病负担。

原始出处

Gregg EW1, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L.Changes in diabetes-related complications in the United States, 1990-2010.N Engl J Med. 2014 Apr 17

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690181, encodeId=1bf8169018100, content=<a href='/topic/show?id=3f6c3e928af' target=_blank style='color:#2F92EE;'>#发病趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37928, encryptionId=3f6c3e928af, topicName=发病趋势)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7e928986386, createdName=12498f6em16暂无昵称, createdTime=Mon Oct 13 05:05:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648763, encodeId=3f9b1648e6372, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Fri Mar 13 04:05:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757605, encodeId=87f21e5760550, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Nov 07 19:05:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800303, encodeId=f0e31800303a4, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Sep 18 21:05:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9101, encodeId=88d5910143, content=关键为什么快速增加?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 22 16:05:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690181, encodeId=1bf8169018100, content=<a href='/topic/show?id=3f6c3e928af' target=_blank style='color:#2F92EE;'>#发病趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37928, encryptionId=3f6c3e928af, topicName=发病趋势)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7e928986386, createdName=12498f6em16暂无昵称, createdTime=Mon Oct 13 05:05:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648763, encodeId=3f9b1648e6372, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Fri Mar 13 04:05:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757605, encodeId=87f21e5760550, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Nov 07 19:05:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800303, encodeId=f0e31800303a4, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Sep 18 21:05:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9101, encodeId=88d5910143, content=关键为什么快速增加?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 22 16:05:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2015-03-13 yaanren
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690181, encodeId=1bf8169018100, content=<a href='/topic/show?id=3f6c3e928af' target=_blank style='color:#2F92EE;'>#发病趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37928, encryptionId=3f6c3e928af, topicName=发病趋势)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7e928986386, createdName=12498f6em16暂无昵称, createdTime=Mon Oct 13 05:05:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648763, encodeId=3f9b1648e6372, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Fri Mar 13 04:05:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757605, encodeId=87f21e5760550, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Nov 07 19:05:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800303, encodeId=f0e31800303a4, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Sep 18 21:05:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9101, encodeId=88d5910143, content=关键为什么快速增加?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 22 16:05:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-11-07 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690181, encodeId=1bf8169018100, content=<a href='/topic/show?id=3f6c3e928af' target=_blank style='color:#2F92EE;'>#发病趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37928, encryptionId=3f6c3e928af, topicName=发病趋势)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7e928986386, createdName=12498f6em16暂无昵称, createdTime=Mon Oct 13 05:05:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648763, encodeId=3f9b1648e6372, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Fri Mar 13 04:05:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757605, encodeId=87f21e5760550, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Nov 07 19:05:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800303, encodeId=f0e31800303a4, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Sep 18 21:05:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9101, encodeId=88d5910143, content=关键为什么快速增加?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 22 16:05:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690181, encodeId=1bf8169018100, content=<a href='/topic/show?id=3f6c3e928af' target=_blank style='color:#2F92EE;'>#发病趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37928, encryptionId=3f6c3e928af, topicName=发病趋势)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7e928986386, createdName=12498f6em16暂无昵称, createdTime=Mon Oct 13 05:05:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648763, encodeId=3f9b1648e6372, content=<a href='/topic/show?id=699b233e229' target=_blank style='color:#2F92EE;'>#乐观#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23372, encryptionId=699b233e229, topicName=乐观)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79123671906, createdName=yaanren, createdTime=Fri Mar 13 04:05:00 CST 2015, time=2015-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757605, encodeId=87f21e5760550, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Fri Nov 07 19:05:00 CST 2014, time=2014-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1800303, encodeId=f0e31800303a4, content=<a href='/topic/show?id=dc8be25311a' target=_blank style='color:#2F92EE;'>#相关并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72531, encryptionId=dc8be25311a, topicName=相关并发症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce5632, createdName=jianjun66, createdTime=Thu Sep 18 21:05:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=9101, encodeId=88d5910143, content=关键为什么快速增加?, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Apr 22 16:05:00 CST 2014, time=2014-04-22, status=1, ipAttribution=)]
    2014-04-22 匿名用户

    关键为什么快速增加?

    0

相关资讯

AHJ:增加糖尿病风险的心血管药物

世界范围内,2型糖尿病的患病率持续快速增加,2012年,全球有超过3.71亿糖尿病患者。糖尿病也因此成为心血管疾病普遍的危险因素,而且有越来越多的心血管疾病患者患有糖尿病。在心血管疾病患者中,糖尿病是不良预后的高危因素。 控制血压、低密度脂蛋白胆固醇和糖化血红蛋白(HbA1C)可降低糖尿病患者心血管风险,尽管使用的药物越来越多,但只有少部分患者成功地达到了上述目标。 在此背景下,一些用于降低心

OJPM:糖尿病给发展中国家带来的负担

糖尿病是一种代谢疾病,分为四种类型:1型糖尿病、2型糖尿病、妊娠糖尿病及其他特殊类型。根据美国糖尿病协会标准,糖尿病被定义为糖化血红蛋白(Hb A1C)≥6.5%,空腹血糖(FPG)≥126 mg/dl,口服普通糖耐量试验(OGTT)≥200 mg/dl。【原文下载】 糖尿病流行率高、发病率高、持续时间长和治疗成本高。1993年,世界卫生组织发布的全球标准化的糖尿病的患病率估算表明,成人糖尿

Nature:治疗肥胖和糖尿病的基因标靶

日前,英国《自然》杂志刊登的一项研究发现,通过基因调节、抑制一种酶发挥作用,可以提高新陈代谢效率,并改善葡萄糖耐受不良状况。这一成果有望帮助开发治疗肥胖和糖尿病的新方法。来自哈佛医学院(HMS)等机构的研究人员表示,新陈代谢偏慢、效率偏低是导致肥胖和 2 型糖尿病等代谢类疾病的重要原因。如果找到加速新陈代谢的基因“开关”,就有望从根本上解决此类问题。他们在动物实验中发现,患有糖尿病或是肥胖的实验鼠

Diabetes Care:双臂血压差大或增糖尿病患者死亡风险

一项英国研究显示,在对糖尿病患者进行初始临床评估时,应测量双臂的收缩压,双臂收缩压差可能与致残率和死亡率风险增加相关。文章3月25日在线发表于《糖尿病护理》(Diabetes Care)杂志。此前在糖尿病领域尚未有过这样的研究,试验者在糖尿病患者和非患者之间,评估了参考标准和测量技术,以此来考察双臂血压差与糖尿病的之间的联系。研究纳入了727例1型或者2型糖尿病患者,285名非糖尿病作为对照者。8

糖尿病移动管理平台上线

4月15日,由北京市糖尿病防治协会主办的2014年北京市糖尿病教育与管理大会在京举行。会上,国内首个将糖尿病患者管理目标量化的实践项目“8760健康行动”移动互联管理平台正式上线。 2013年,北京市糖尿病防治协会启动“8760健康行动”——中国2型糖尿病自我管理教育及支持项目。该协会理事长、北京协和医院陈伟教授说,项目旨在帮助糖尿病患者实现控制血糖平稳、调理代谢平衡、预防急性并发症、延缓慢性

N Engl J Med:糖尿病患者并发心梗中风比率下降

糖尿病困扰着成千上万的美国人。周三,联邦机构的研究人员首次通报了全国范围内对抗最具破坏性的糖尿病并发症取得的总体进展,发现心肌梗死、中风、肾衰竭和截肢的几率在过去二十年里显著降低。研究涉及的时间是从1990年到2010年。在这期间,下降最显著的是心肌梗死和死于高血糖的几率,降幅超过60%。尽管研究人员掌握的分布不均的迹象表明,最近几年糖尿病患者的结局一直在改善,但发表在《新英格兰医学杂志》(T

Baidu
map
Baidu
map
Baidu
map